Buzz Stocks: Tesla, ARIAD Pharma, and Uniqure NV

Today's stocks to watch in the news include Tesla Motors Inc (TSLA), Ariad Pharmaceuticals, Inc. (ARIA), and Uniqure NV (QURE)

by Alex Eppstein

Published on Apr 6, 2015 at 9:23 AM
Updated on Jun 29, 2020 at 11:38 AM

U.S. stocks are bracing for a steep drop out of the gate, following a lackluster nonfarm payrolls report on Friday. In company news, today's stocks to watch include electric automaker Tesla Motors Inc (NASDAQ:TSLA), as well as drugmakers Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) and Uniqure NV (NASDAQ:QURE).

  • TSLA achieved a quarterly record for most car deliveries during the first three months of 2015. Roughly 10,000 vehicles were sold within that time frame -- a 55% year-over-year jump -- though the pace is well short of CEO Elon Musk's projected 55,000 deliveries for the year. Ahead of the bell, Tesla Motors Inc is pointed 4% north of Thursday's close at $191, continuing its recent bounce from support in the round $180 region. Should the shares continue to display technical strength, there's plenty of sideline cash available to fuel additional gains. Roughly one-quarter of TSLA's float is sold short, which would take nearly a week to cover, at the equity's average daily trading volume.

  • ARIA is 3% higher in electronic trading, after the firm's Iclusig leukemia treatment was granted regulatory approval for use in Canada. Technically speaking, the security has had a successful 2015 so far, rallying 19.1% to trade at $8.18. Not surprisingly, traders on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) have been buying to open calls over puts at a breakneck pace of late. Ariad Pharmaceuticals, Inc.'s 10-day call/put volume ratio of 30.01 indicates 30 calls have been bought to open for every put during the last two weeks -- a ratio that ranks in the 79th percentile of its annual range.

  • Finally, QURE is surging in pre-market trading, up 46.1% after the firm announced a gene therapy partnership with Bristol-Myers Squibb Co (NYSE:BMY). As part of the deal, BMY will pay $33.84 per share to secure a 4.9% equity stake in Uniqure NV -- a 48% premium to Thursday's closing price of $22.86. Longer term, it's been a banner year for QURE, which has outperformed the broader S&P 500 Index (SPX) by more than 30 percentage points over the past three months. As such, all four analysts covering QURE have given the shares a "strong buy" recommendation.

A Schaeffer's 39th Anniversary Exclusive!

8 Top Stock Picks for 2020

Access your FREE insider report before it's too late!


  
 
 

Partnercenter